



AMERICAN ACADEMY™
OF OPHTHALMOLOGY

12

Retina and Vitreous

Last major revision 2015–2016

2017–2018
BCSC
**Basic and Clinical
Science Course™**

*Funded in part by the Educational Trust
Fund/Retina Research Foundation*

The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this enduring material for a maximum of 15 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME expiration date: June 1, 2018. *AMA PRA Category 1 Credits*[™] may be claimed only once between June 1, 2015, and the expiration date.

BCSC[®] volumes are designed to increase the physician's ophthalmic knowledge through study and review. Users of this activity are encouraged to read the text and then answer the study questions provided at the back of the book.

To claim *AMA PRA Category 1 Credits*[™] upon completion of this activity, learners must demonstrate appropriate knowledge and participation in the activity by taking the posttest for Section 12 and achieving a score of 80% or higher. For further details, please see the instructions for requesting CME credit at the back of the book.

The Academy provides this material for educational purposes only. It is not intended to represent the only or best method or procedure in every case, nor to replace a physician's own judgment or give specific advice for case management. Including all indications, contraindications, side effects, and alternative agents for each drug or treatment is beyond the scope of this material. All information and recommendations should be verified, prior to use, with current information included in the manufacturers' package inserts or other independent sources, and considered in light of the patient's condition and history. Reference to certain drugs, instruments, and other products in this course is made for illustrative purposes only and is not intended to constitute an endorsement of such. Some material may include information on applications that are not considered community standard, that reflect indications not included in approved FDA labeling, or that are approved for use only in restricted research settings. **The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate, informed patient consent in compliance with applicable law.** The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise from the use of any recommendations or other information contained herein.

AAO, AAOE, American Academy of Ophthalmology, Basic and Clinical Science Course, BCSC, EyeCare America, EyeNet, EyeSmart, EyeWiki, Focal Points, IRIS, ISRS, OKAP, ONE, Ophthalmic Technology Assessments, *Ophthalmology*, Preferred Practice Pattern, ProVision, SmartSight, The Ophthalmic News & Education Network, and the AAO logo (shown on cover) and tagline (Protecting Sight. Empowering Lives.) are, among other marks, the registered trademarks and trademarks of the American Academy of Ophthalmology.

Cover image: From BCSC Section 5, *Neuro-Ophthalmology*. Fundus photograph showing an arteriovenous malformation (racemose angioma) of the retina in a patient with Wyburn-Mason syndrome. (Courtesy of Mark J. Greenwald, MD.)

Copyright © 2017 American Academy of Ophthalmology. All rights reserved.
No part of this publication may be reproduced without written permission.

Printed in the United States of America.

Basic and Clinical Science Course

Louis B. Cantor, MD, Indianapolis, Indiana, *Senior Secretary for Clinical Education*

Christopher J. Rapuano, MD, Philadelphia, Pennsylvania, *Secretary for Lifelong Learning and Assessment*

George A. Cioffi, MD, New York, New York, *BCSC Course Chair*

Section 12

Faculty

Colin A. McCannel, MD, *Chair*, Los Angeles, California

Neal H. Atebara, MD, Honolulu, Hawaii

Stephen Jae Kim, MD, Nashville, Tennessee

Brian C. Leonard, MD, Ottawa, Canada

Richard B. Rosen, MD, New York, New York

David Sarraf, MD, Los Angeles, California

Emmett Cunningham, Jr, MD, PhD, MPH, *Consultant*, Hillsborough, California

Graham E. Holder, PhD, *Consultant*, London, England

The Academy wishes to acknowledge the American Society of Retina Specialists (ASRS), the Macula Society, and the Retina Society for recommending faculty members to the BCSC Section 12 committee.

The Academy also wishes to acknowledge the following committees for review of this edition:

Committee on Aging: Helen Ka-Fun Li, MD, Houston, Texas

Vision Rehabilitation Committee: Joseph L. Fontenot, Daphne, Texas

Practicing Ophthalmologists Advisory Committee for Education: David J. Browning, MD, PhD, *Primary Reviewer*, Charlotte, North Carolina; Edward K. Isbey III, MD, *Chair*, Asheville, North Carolina; Alice L. Bashinsky, MD, Asheville, North Carolina; Robert G. Fante, MD, Denver, Colorado; Bradley D. Fouraker, MD, Tampa, Florida; Dasa V. Gangadhar, MD, Wichita, Kansas; Steven J. Grosser, MD, Golden Valley, Minnesota; James A. Savage, MD, Memphis, Tennessee



European Board of Ophthalmology: Alain Gaudric, MD, *Chair*, Paris, France; Catherine Creuzot-Garcher, MD, PhD, FEBO, *Liaison*, Dijon, France; Bahram Bodaghi, MD, PhD, Paris, France; Giovanni Staurenghi, MD, Milan, Italy; Adnan Tufail, MBBS, MD, London, United Kingdom

The EBO wishes to acknowledge EURETINA for recommending reviewers to the EBO committee.

Financial Disclosures

Academy staff members who contributed to the development of this product state that within the past 12 months, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.

The authors and reviewers state that within the past 12 months, they have had the following financial relationships:*

Dr Bodaghi: Abbott Medical Optics (C), Allergan (C, S), Bausch + Lomb Surgical (C), Novartis Pharmaceuticals (S), Santen (C), Xoma (C)

Dr Browning: Aerpio Therapeutics (S), Alimera Sciences (C), Diabetic Retinopathy Clinical Research Network (S), Genentech (S), Novartis Pharmaceuticals (S), Pfizer (S), Regeneron Pharmaceuticals (S)

Dr Creuzot-Garcher: Alcon Laboratories (C, S), Bausch + Lomb (C), Laboratoires Thea (C), Novartis Pharmaceuticals (C, L, S)

Dr Fante: Ophthalmic Mutual Insurance Company (C)

Dr Fouraker: Addition Technology (C), Alcon Laboratories (C), KeraVision (C), Ophthalmic Mutual Insurance Company (C)

Dr Gaudric: Alcon Laboratories (C), Alimera Sciences (C), Bayer (C), Novartis Pharmaceuticals (C, S), ThromboGenics (C)

Dr Grosser: Ivantis (O)

Dr Holder: Servier (C), Isis Pharmaceuticals (C)

Dr Isbey: Alcon Laboratories (S), Bausch + Lomb (S)

Dr Leonard: Annidis (O), Bayer Healthcare Pharmaceuticals (C), Merck & Co (C), Novartis Pharmaceuticals (C), Orbis International (C), Pfizer (S), Regeneron Pharmaceuticals (C)

Dr McCannel: DORC Dutch Ophthalmic Research Center (International)/Dutch Ophthalmic USA (C)

Dr Rosen: Allergan (S), Clarity Medical Systems (C), Genentech (S), OD-OS (L), Optovue (C)

Dr Sarraf: Alcon Laboratories (S), Allergan (S), DORC Dutch Ophthalmic Research Center (International)/Dutch Ophthalmic USA (S), Genentech (S), Heidelberg Engineering (L), Regeneron Pharmaceuticals (S), ThromboGenics (S)

Dr Savage: Allergan (L)

Dr Staurengi: Alcon Laboratories (C, L), Allergan (C), Bayer (C, L), Canon (C), Glaxo-SmithKline (C), Heidelberg Engineering (C, L), Kowa (S), Novartis Pharmaceuticals (C, L, S), Ocular Instruments (P), OD-OS (C), Optos (C), Optovue (C), QLT Phototherapeutics (C), Roche (C), Zeiss (S)

Dr Tufail: Alcon Laboratories (C), Allergan (C, L), Bayer Healthcare Pharmaceuticals (C), Genentech (C), Heidelberg Engineering (C), Notal Vision (S), Novartis Pharmaceuticals (C, L, S)

The other authors and reviewers state that within the past 12 months, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.

*C = consultant fees, paid advisory boards, or fees for attending a meeting; L = lecture fees (honoraria), travel fees, or reimbursements when speaking at the invitation of a commercial sponsor; O = equity ownership/stock options of publicly or privately traded firms (excluding mutual funds) with manufacturers of commercial ophthalmic products or commercial ophthalmic services; P = patents and/or royalties that might be viewed as creating a potential conflict of interest; S = grant support for the past year (all sources) and all sources used for a specific talk or manuscript with no time limitation

Recent Past Faculty

Richard S. Kaiser, MD

Adam A. Martidis, MD

Hermann D. Schubert, MD

David N. Zacks, MD, PhD

In addition, the Academy gratefully acknowledges the contributions of numerous past faculty and advisory committee members who have played an important role in the development of previous editions of the Basic and Clinical Science Course.

American Academy of Ophthalmology Staff

Dale E. Fajardo, *Vice President, Education*

Beth Wilson, *Director, Continuing Professional Development*

Ann McGuire, *Acquisitions and Development Manager*

Stephanie Tanaka, *Publications Manager*

D. Jean Ray, *Production Manager*

Kimberly Torgerson, *Publications Editor*

Beth Collins, *Medical Editor*

Naomi Ruiz, *Publications Specialist*

American Academy of Ophthalmology
655 Beach Street
Box 7424
San Francisco, CA 94120-7424

Contents

| | |
|--|-----------|
| General Introduction | xv |
| Objectives | 1 |
| Introduction | 3 |
| PART I Fundamentals and Diagnostic Approaches | 5 |
| 1 Basic Anatomy | 7 |
| The Vitreous | 7 |
| Neurosensory Retina | 8 |
| Retinal Pigment Epithelium | 15 |
| Bruch Membrane | 17 |
| Choroid | 17 |
| Sclera | 18 |
| 2 Diagnostic Approach to Retinal Disease | 21 |
| Techniques of Examination | 21 |
| Ophthalmoscopy | 21 |
| Imaging Technologies | 22 |
| Scanning Laser Ophthalmoscopy | 22 |
| Optical Coherence Tomography | 23 |
| Fundus Autofluorescence | 26 |
| Retinal Angiographic Techniques | 28 |
| B-Scan Ultrasonography | 34 |
| 3 Retinal Physiology and Psychophysics | 37 |
| Electroretinography | 37 |
| Full-Field (Ganzfeld) ERG | 38 |
| Multifocal ERG | 42 |
| Pattern ERG | 42 |
| Clinical Considerations | 42 |
| Electro-oculography | 44 |
| Visual Evoked Cortical Potentials | 46 |
| Psychophysical Testing | 47 |
| Contrast Sensitivity | 48 |
| Color Vision | 49 |
| Dark Adaptation | 52 |
| Photostress Recovery Time | 53 |

PART II Disorders of the Retina and Vitreous 55

4 Age-Related Macular Degeneration and Other Causes of Choroidal Neovascularization 57

Age-Related Macular Degeneration 57

 Genetics and AMD 58

 Nonneovascular AMD 59

 Neovascular AMD 66

Other Causes of Choroidal Neovascularization 79

 Ocular Histoplasmosis Syndrome 79

 Angioid Streaks 81

 Pathologic Myopia 82

 Idiopathic CNV and Miscellaneous Causes of CNV 83

5 Retinal Vascular Disease: Diabetic Retinopathy 85

Terminology and Classification 85

 Diabetes Terminology 85

 Diabetic Retinopathy Terminology 85

Epidemiology of Diabetic Retinopathy 86

 The Wisconsin Epidemiologic Study of Diabetic Retinopathy 86

Pathogenesis of Diabetic Retinopathy 87

Systemic Medical Management of Diabetic Retinopathy 88

Abnormalities Associated With Vision Loss From Diabetic Retinopathy 92

Nonproliferative Diabetic Retinopathy 92

 Diabetic Macular Edema 92

 Diabetic Macular Ischemia 100

 Severe Nonproliferative Diabetic Retinopathy 100

Proliferative Diabetic Retinopathy 101

 Management of Proliferative Diabetic Retinopathy and Its Complications 102

 Vitrectomy Surgery for Complications of Diabetic Retinopathy 106

Cataract Surgery in Patients With Diabetes Mellitus 107

Recommended Diabetes-Related Ophthalmic Examinations 108

6 Retinal Vascular Diseases Associated With Cardiovascular Disease 111

Systemic Arterial Hypertension 111

 Hypertensive Retinopathy 111

 Hypertensive Choroidopathy 113

 Hypertensive Optic Neuropathy 113

Retinal Vein Occlusion 115

 Branch Retinal Vein Occlusion 117

 Central Retinal Vein Occlusion 120

Ocular Ischemic Syndrome and Retinopathy of Carotid Occlusive Disease 127

 Symptoms and Signs 127

| | |
|--|------------|
| Etiology and Course | 129 |
| Treatment of Ocular Ischemic Syndrome | 129 |
| Arterial Occlusive Disease | 129 |
| Capillary Retinal Arteriole Obstruction (Cotton-Wool Spots) | 129 |
| Branch Retinal Artery Occlusion | 130 |
| Cilioretinal Artery Occlusion | 132 |
| Central Retinal Artery Occlusion | 132 |
| Ophthalmic Artery Occlusion. | 135 |
| Arterial Macroaneurysms | 136 |
| 7 Other Retinal Vascular Diseases. | 137 |
| Sickle Cell Retinopathy | 137 |
| Nonproliferative Sickle Cell Retinopathy | 138 |
| Proliferative Sickle Cell Retinopathy | 138 |
| Other Ocular Abnormalities in Sickle Cell Hemoglobinopathies | 141 |
| Management of Sickle Cell Retinopathy | 141 |
| Vasculitis | 142 |
| Cystoid Macular Edema | 143 |
| Etiologies for CME | 143 |
| Incidence of CME. | 144 |
| Treatment for CME | 145 |
| Coats Disease | 145 |
| Parafoveal (Juxtafoveal) Retinal Telangiectasia | 147 |
| Phakomatoses | 149 |
| Von Hippel–Lindau Disease | 149 |
| Wyburn-Mason Syndrome | 150 |
| Retinal Cavernous Hemangioma | 152 |
| Radiation Retinopathy. | 153 |
| Valsalva Retinopathy | 154 |
| Purtscher Retinopathy and Purtscherlike Retinopathy | 154 |
| Terson Syndrome. | 156 |
| 8 Retinopathy of Prematurity | 157 |
| Introduction | 157 |
| Epidemiology. | 157 |
| Terminology and Classification | 157 |
| Pathophysiology of ROP | 161 |
| Natural Course | 162 |
| Associated Conditions and Late Sequelae. | 162 |
| Screening Recommendations. | 163 |
| Screening Criteria | 163 |
| Screening Intervals | 163 |
| Fundus Photographic Screening of ROP | 164 |
| Prevention and Risk Factors | 165 |
| Treatment | 165 |
| Laser and Cryoablation Surgery | 166 |
| Anti-VEGF Drugs. | 167 |
| Vitrectomy and Scleral Buckling Surgery | 168 |

| | | |
|-----------|---|------------|
| 9 | Choroidal Disease | 169 |
| | Central Serous Chorioretinopathy. | 169 |
| | Optical Coherence Tomography. | 170 |
| | Fluorescein Angiography. | 170 |
| | Indocyanine Green Angiography | 172 |
| | Fundus Autofluorescence Imaging. | 172 |
| | Differential Diagnosis | 172 |
| | Natural Course and Management | 173 |
| | Choroidal Perfusion Abnormalities | 173 |
| | Increased Venous Pressure | 174 |
| | Hypertension. | 174 |
| | Inflammatory Conditions | 176 |
| | Thromboembolic Disease | 177 |
| | Iatrogenic Abnormalities. | 177 |
| | Choroidal Hemangiomas | 177 |
| | Uveal Effusion Syndrome | 179 |
| | Bilateral Diffuse Uveal Melanocytic Proliferation | 180 |
| | | |
| 10 | Focal and Diffuse Choroidal and Retinal Inflammation | 183 |
| | Noninfectious Retinal and Choroidal Inflammation | 183 |
| | White Dot Syndromes | 183 |
| | Chorioretinal Autoimmune Conditions | 191 |
| | Sympathetic Ophthalmia. | 195 |
| | Uveitis Masquerade: Intraocular Lymphoma | 195 |
| | Infectious Retinal and Choroidal Inflammation | 196 |
| | Cytomegalovirus Retinitis | 196 |
| | Non-CMV Necrotizing Herpetic Retinitis | 197 |
| | Endogenous Bacterial Endophthalmitis | 199 |
| | Fungal Endophthalmitis | 200 |
| | Tuberculosis | 202 |
| | Syphilitic Chorioretinitis | 203 |
| | Cat-Scratch Disease | 204 |
| | Toxoplasmic Retinochoroiditis | 204 |
| | Toxocariasis | 206 |
| | Lyme Disease. | 207 |
| | Diffuse Unilateral Subacute Neuroretinitis | 207 |
| | West Nile Virus Chorioretinitis | 208 |
| | | |
| 11 | Congenital and Stationary Retinal Disease | 209 |
| | Color Vision (Cone System) Abnormalities. | 209 |
| | Congenital Color Deficiency | 209 |
| | Night Vision (Rod System) Abnormalities | 211 |
| | Congenital Night-Blinding Disorders With Normal Fundi | 211 |
| | Congenital Night-Blinding Disorders With Fundus Abnormality | 213 |

| | | |
|-----------|---|------------|
| 12 | Hereditary Retinal and Choroidal Dystrophies | 215 |
| | Diagnostic and Prognostic Testing | 216 |
| | Diffuse Photoreceptor Dystrophies | 217 |
| | Retinitis Pigmentosa | 218 |
| | Leber Congenital Amaurosis | 223 |
| | Cone Dystrophies | 224 |
| | Macular Dystrophies | 226 |
| | Stargardt Disease | 226 |
| | Vitelliform Degenerations | 227 |
| | Early-Onset Drusen | 230 |
| | Pattern Dystrophies | 232 |
| | Sorsby Macular Dystrophy | 233 |
| | Choroidal Dystrophies | 234 |
| | Diffuse Degenerations | 234 |
| | Regional and Central Choroidal Dystrophies | 235 |
| | Inner Retinal and Vitreoretinal Dystrophies | 237 |
| | X-Linked Retinoschisis | 237 |
| | Enhanced S-Cone Syndrome | 238 |
| | | |
| 13 | Retinal Degenerations Associated With Systemic Disease | 239 |
| | Retinal Degeneration With Systemic Involvement | 239 |
| | Infantile-Onset to Early Childhood-Onset Syndromes | 239 |
| | Bardet-Biedl Syndrome | 242 |
| | Hearing Loss and Pigmentary Retinopathy: Usher Syndrome | 243 |
| | Neuromuscular Disorders | 244 |
| | Other Organ System Disorders | 244 |
| | Paraneoplastic and Autoimmune Retinopathies | 246 |
| | Metabolic Diseases | 247 |
| | Albinism | 247 |
| | Central Nervous System Metabolic Abnormalities | 248 |
| | Amino Acid Disorders | 253 |
| | Mitochondrial Disorders | 254 |
| | | |
| 14 | Systemic Drug-Induced Retinal Toxicity | 257 |
| | Drugs Causing Abnormalities of the Retinal Pigment Epithelium/Photoreceptor Complex | 257 |
| | Chloroquine Derivatives | 257 |
| | Phenothiazines | 259 |
| | Miscellaneous Medications | 260 |
| | Drugs Causing Occlusive Retinopathy or Microvasculopathy | 262 |
| | Drugs Causing Ganglion Cell and Optic Nerve Toxicity | 262 |
| | Drugs Causing Macular Edema | 263 |
| | Drugs Causing Crystalline Retinopathy | 264 |
| | Drugs Causing Abnormalities in Color Vision and Electroretinography | 266 |
| | Miscellaneous Drugs Causing Ocular Toxicities | 266 |

| | | |
|-----------|--|------------|
| 15 | Retinal Detachment and Predisposing Lesions | 267 |
| | Retinal Breaks | 267 |
| | Traumatic Breaks | 268 |
| | Trauma in Young Eyes | 268 |
| | Posterior Vitreous Detachment | 269 |
| | Examination and Management of Posterior Vitreous Detachment | 271 |
| | Lesions Predisposing Eyes to Retinal Detachment | 272 |
| | Lattice Degeneration. | 272 |
| | Vitreoretinal Tufts. | 273 |
| | Meridional Folds, Enclosed Ora Bays, and Peripheral Retinal Excavations | 274 |
| | Lesions Not Predisposing Eyes to Retinal Detachment | 275 |
| | Paving-Stone Degeneration. | 275 |
| | Retinal Pigment Epithelial Hyperplasia. | 275 |
| | Retinal Pigment Epithelial Hypertrophy | 276 |
| | Peripheral Cystoid Degeneration | 276 |
| | Prophylactic Treatment of Retinal Breaks | 276 |
| | Symptomatic Retinal Breaks | 277 |
| | Asymptomatic Retinal Breaks. | 277 |
| | Lattice Degeneration. | 278 |
| | Aphakia and Pseudophakia | 278 |
| | Fellow Eye in Patients With Retinal Detachment. | 278 |
| | Subclinical Retinal Detachment | 278 |
| | Retinal Detachment. | 279 |
| | Rhegmatogenous Retinal Detachment | 279 |
| | Tractional Retinal Detachment | 283 |
| | Exudative Retinal Detachment | 283 |
| | Differential Diagnosis of Retinal Detachment. | 284 |
| | Retinoschisis | 284 |
| | Differentiation of Retinoschisis From Rhegmatogenous Retinal Detachment. | 285 |
| | Macular Lesions Associated With Retinal Detachment. | 286 |
| | Optic Pit Maculopathy. | 286 |
| | Macular Holes in High Myopia | 287 |
| 16 | Diseases of the Vitreous and Vitreoretinal Interface | 289 |
| | Posterior Vitreous Detachment | 289 |
| | Epiretinal Membranes | 290 |
| | Vitreomacular Traction Diseases | 293 |
| | Idiopathic Macular Holes. | 294 |
| | Developmental Abnormalities | 297 |
| | Tunica Vasculosa Lentis | 297 |
| | Prepapillary Vascular Loops | 297 |
| | Persistent Fetal Vasculature. | 298 |

Hereditary Hyaloideoretinopathies With Optically Empty Vitreous:
 Wagner and Stickler Syndromes 299
 Familial Exudative Vitreoretinopathy 300
 Vitreous Opacities 301
 Asteroid Hyalosis 301
 Vitreous Hemorrhage 302
 Pigment Granules 302
 Cholesterolosis 302
 Amyloidosis 303
 Vitreous Abnormalities Secondary to Surgery. 304

17 Posterior Segment Manifestations of Trauma 305

Evaluation of the Patient After Ocular Trauma 305
 Blunt Trauma 306
 Vitreous Hemorrhage 307
 Comotio Retinae 307
 Choroidal Rupture 307
 Posttraumatic Macular Hole 309
 Traumatic Chorioretinal Disruption (Retinal Sclopetaria) 311
 Scleral Rupture 311
 Lacerating and Penetrating Injuries 312
 Perforating Injuries 313
 Intraocular Foreign Bodies. 313
 Surgical Techniques for Removal of Intraocular Foreign Bodies 315
 Retained Intraocular Foreign Bodies. 315
 Posttraumatic Endophthalmitis 316
 Sympathetic Ophthalmia 317
 Abusive Head Trauma. 317
 Avulsion of the Optic Disc 318
 Photic Damage 319
 Solar Retinopathy 320
 Phototoxicity From Ophthalmic Instrumentation 320
 Occupational Light Toxicity 321
 Handheld Laser-Pointer Injury 321

PART III Selected Therapeutic Topics 323

18 Laser Therapy for Posterior Segment Diseases 325

Basic Principles of Photocoagulation 325
 Choice of Laser Wavelength 325
 Practical Aspects of Laser Photocoagulation 327
 Complications of Photocoagulation 330
 Transpupillary Thermotherapy 332
 Photodynamic Therapy 332
 Complications of Photodynamic Therapy. 332

| | | |
|-----------|--|------------|
| 19 | Vitreoretinal Surgery and Intravitreal Injections | 333 |
| | Pars Plana Vitrectomy | 333 |
| | Vitrectomy for Selected Macular Diseases | 334 |
| | Macular Epiretinal Membranes | 334 |
| | Vitreomacular Traction Diseases | 334 |
| | Submacular Hemorrhage | 337 |
| | Vitrectomy for Complications of Diabetic Retinopathy | 338 |
| | Vitreous Hemorrhage | 338 |
| | Diabetic Tractional Retinal Detachment | 339 |
| | Diabetic Macular Edema | 340 |
| | Vitrectomy for Posterior Segment Complications | |
| | of Anterior Segment Surgery | 340 |
| | Postoperative Endophthalmitis | 340 |
| | Retained Lens Fragments After Phacoemulsification | 343 |
| | Posteriorly Dislocated Intraocular Lenses | 345 |
| | Cystoid Macular Edema | 345 |
| | Suprachoroidal Hemorrhage | 345 |
| | Needle Penetration of the Globe | 347 |
| | Rhegmatogenous Retinal Detachment Surgery | 348 |
| | Techniques for Surgical Repair of Retinal Detachments | 349 |
| | Outcomes Following Retinal Reattachment Surgery | 353 |
| | Complications of Pars Plana Vitrectomy | 354 |
| | Intravitreal Injections | 355 |
| | Basic Texts | 357 |
| | Related Academy Materials | 359 |
| | Requesting Continuing Medical Education Credit | 361 |
| | Study Questions | 363 |
| | Answer Sheet for Section 12 Study Questions | 373 |
| | Answers | 375 |
| | Index | 381 |

General Introduction

The Basic and Clinical Science Course (BCSC) is designed to meet the needs of residents and practitioners for a comprehensive yet concise curriculum of the field of ophthalmology. The BCSC has developed from its original brief outline format, which relied heavily on outside readings, to a more convenient and educationally useful self-contained text. The Academy updates and revises the course annually, with the goals of integrating the basic science and clinical practice of ophthalmology and of keeping ophthalmologists current with new developments in the various subspecialties.

The BCSC incorporates the effort and expertise of more than 90 ophthalmologists, organized into 13 Section faculties, working with Academy editorial staff. In addition, the course continues to benefit from many lasting contributions made by the faculties of previous editions. Members of the Academy Practicing Ophthalmologists Advisory Committee for Education, Committee on Aging, and Vision Rehabilitation Committee review every volume before major revisions. Members of the European Board of Ophthalmology, organized into Section faculties, also review each volume before major revisions, focusing primarily on differences between American and European ophthalmology practice.

Organization of the Course

The Basic and Clinical Science Course comprises 13 volumes, incorporating fundamental ophthalmic knowledge, subspecialty areas, and special topics:

- 1 Update on General Medicine
- 2 Fundamentals and Principles of Ophthalmology
- 3 Clinical Optics
- 4 Ophthalmic Pathology and Intraocular Tumors
- 5 Neuro-Ophthalmology
- 6 Pediatric Ophthalmology and Strabismus
- 7 Orbit, Eyelids, and Lacrimal System
- 8 External Disease and Cornea
- 9 Intraocular Inflammation and Uveitis
- 10 Glaucoma
- 11 Lens and Cataract
- 12 Retina and Vitreous
- 13 Refractive Surgery

In addition, a comprehensive Master Index allows the reader to easily locate subjects throughout the entire series.

References

Readers who wish to explore specific topics in greater detail may consult the references cited within each chapter and listed in the Basic Texts section at the back of the book.

These references are intended to be selective rather than exhaustive, chosen by the BCSC faculty as being important, current, and readily available to residents and practitioners.

Videos

This edition of Section 12, *Retina and Vitreous*, includes videos related to topics covered in the book. The videos were selected by members of the BCSC faculty and are available to readers of the print and electronic versions of Section 12. Mobile-device users can scan the QR code below (a QR-code reader must already be installed on the device) to access the video content.

Study Questions and CME Credit

Each volume of the BCSC is designed as an independent study activity for ophthalmology residents and practitioners. The learning objectives for this volume are given on page 1. The text, illustrations, and references provide the information necessary to achieve the objectives; the study questions allow readers to test their understanding of the material and their mastery of the objectives. Physicians who wish to claim CME credit for this educational activity may do so by following the instructions given at the end of the book.

Conclusion

The Basic and Clinical Science Course has expanded greatly over the years, with the addition of much new text, numerous illustrations, and video content. Recent editions have sought to place greater emphasis on clinical applicability while maintaining a solid foundation in basic science. As with any educational program, it reflects the experience of its authors. As its faculties change and medicine progresses, new viewpoints emerge on controversial subjects and techniques. Not all alternate approaches can be included in this series; as with any educational endeavor, the learner should seek additional sources, including Academy Preferred Practice Pattern Guidelines.

The BCSC faculty and staff continually strive to improve the educational usefulness of the course; you, the reader, can contribute to this ongoing process. If you have any suggestions or questions about the series, please do not hesitate to contact the faculty or the editors.

The authors, editors, and reviewers hope that your study of the BCSC will be of lasting value and that each Section will serve as a practical resource for quality patient care.

Objectives

Upon completion of BCSC Section 12, *Retina and Vitreous*, the learner should be able to

- describe the basic structure and function of the retina and its relationship to the pigment epithelium, choroid, and vitreous
 - select appropriate methods of examination and ancillary studies for the diagnosis of vitreoretinal disorders
 - identify specific pathologic processes that affect the choroid, retina, or vitreous
 - describe the principles of medical and surgical treatment of vitreoretinal disorders
 - incorporate data from major prospective clinical trials in the management of vitreoretinal disorders whenever possible
-